<DOC>
	<DOC>NCT00851409</DOC>
	<brief_summary>Hereditary angioedema ("HAE") is a disease characterized by recurrent tissue swelling affecting various body locations. Recent literature shows that patients with frequent attacks may benefit from long-term prophylaxis. This study aims to evaluate the safety and prophylactic effect of weekly administrations of 50 IU/kg recombinant C1 Inhibitor ("rhC1INH").</brief_summary>
	<brief_title>A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Aged at least 18 years Signed informed consent Comfirmed diagnosis of HAE with baseline plasma level of functional C1INH activity of less than 50% of normal, and/or proven HAE ,mutation in C1INH gene. A history of anaphylaxis or severe allergy (i.e. requiring medication) to food, proteins and/or drugs. A history of allergic reactions to C1INH products or rabbit protein. Any reported SAE related to study drug administration (withdrawal criterium) Elevated IgE against rabbit dander (&gt;0.35 kU/L; ImmunoCap assay; Phadia) A diagnosis of acquired C1INH deficiency. Woman of child bearing potential, pregnancy or breastfeeding previous treatment within the last 3 months with plasmaderived C1INH Any clinically significant abnormality in the routine haematology, biochemistry and urinalysis Any condition or treatment that in the opinion of the investigator might interfere with the evaluation of the study objectives. Any changes since screening that would exclude subject based on above exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>